[Skip to the guide](#main) [Peptide care The question kit](/) [Guidebook](/#guidebook) [Question desk](/question-desk/) Official records, with context # Read the rule behind the claim. A change needs a clear source. If a seller says a pharmacy is now allowed to make your medicine, ask for the rule that permits it. This page explains what a shortage, a request taken back and a Food and Drug Administration (FDA) meeting can tell you. Care facts checked in September 2026. [Start reading](#copies-and-shortages) Take this question Which current rule permits this preparation, and how does it meet a need that is specific to my care? [Begin here](#copies-and-shortages) On this page [Ask what permits a medicine made to order](#copies-and-shortages) [Taking back a request is not permission to make a medicine](#ingredient-review) [Advice at a meeting is not a new rule](#meeting-record) [Read the sources](#reading) Ask for the answer in plain words. ## Ask what permits a medicine made to order Making a medicine to order is what compounding means. The Food and Drug Administration (FDA) oversees federal drug rules. Federal law limits frequent or large-scale preparation of medicines to order that closely copy products sold ready-made, as of September 2026. There is an exception for a change that makes a significant difference to one named patient, as the prescriber decides. Price savings alone do not qualify for that exception. For example, FDA describes making a medicine to order for a patient allergic to a dye in the ready-made medicine. Ask the prescriber what change is needed for you. When a medicine is on FDA’s national shortage list, rules can allow pharmacies to make copies that would otherwise be restricted. Other compounding rules still apply. Semaglutide and tirzepatide are ingredients in approved medicines for diabetes and weight management. As of September 2026, semaglutide injections and tirzepatide are not on FDA’s national shortage list. A stock gap at one pharmacy gives no permission to make a copy under national shortage rules. Ask in your own words Which current rule permits this preparation, and how does it meet a need that is specific to my care? ## Taking back a request is not permission to make a medicine People or groups had asked FDA to allow certain peptide ingredients for making medicines to order. Several of those requests appear as withdrawn on FDA’s page marked current on April 22, 2026. Withdrawn means the people who submitted the requests took them back. The published concerns about safety remain beside those entries. As of September 2026, withdrawing such a request does not grant FDA approval. For some ingredients still being reviewed, FDA says it will hold off on action if the pharmacy meets stated conditions. That promise is not approval or a statement that making the medicine is legal. Taking back a request does not put the ingredient in that group. It does not give the pharmacy permission to use the ingredient. Ask the pharmacy which current rule allows it to use the exact ingredient in the proposed shot, tablet or other medicine. A changed entry on a web page is not enough to answer that question. ## Advice at a meeting is not a new rule FDA has a list of ingredients allowed for making certain medicines to order. Adding an ingredient requires a rule change. A committee’s advice or vote cannot change that list by itself. At the July 2026 meeting, the ingredients discussed were semax, epitalon, emideltide, MOTS-c, TB-500, KPV and BPC-157. These are ingredient names to compare with a proposed medicine. The meeting considered whether to add them to that list. As of September 2026, FDA had not published the committee’s official vote record, written meeting notes or a transcript, which is a written copy of what was said. Before the meeting, FDA staff had recommended that none of those seven peptide ingredients be added to the list. Published documents show what staff recommended and what the meeting was meant to discuss. They do not show the committee’s final decision. Ask for the final rule and its start date. A suggestion or meeting vote is not proof that the pharmacy is now allowed to make your medicine. Read with a purpose ## The sources behind these questions ### [FDA: follow the shortage updates](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) Read the dated entries in order. A national shortage can allow copies that would otherwise be restricted, but pharmacies must still meet other rules. ### [FDA: read each ingredient table’s heading](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) Check the exact ingredient and the table heading. Taking back a request does not remove FDA’s published safety concerns or mean FDA approved the ingredient. ### [FDA: read the published meeting documents](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) Check what FDA has published about the meeting. Without an official vote record, these documents do not tell you the committee’s final decision. ### [FDA: understand how the allowed-ingredient list changes](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) FDA reviews ingredients and asks for public comments before changing the rule that sets this list. Advice from a committee does not change it. Keep the question moving [A guide to checking care](/) [Choose a different page](/#guidebook) This question kit helps you understand care; this site runs no clinic and does not sell medicines. [Read the source notes](/source-notes/) [Text copy of this page](/source-notes/index.md) [Back to the page start](#main)